- 2014-01-28 14:39:00
Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of c…
- 2014-01-21 17:44:47
The Di Bella Method (DBM) in the treatment of prostate cancer: a preliminary retrospective study of 16 patients and a review of the literature. …
- 2013-11-17 13:41:09
Low-grade Non-Hodgkin Lymphoma at Advanced Stage: A Case Successfully Treated With Cyclophosphamide Plus Somatostatin, Bromocriptine, Retinoids, and M…
- 2014-01-28 14:39:00
The Web site is experiencing technical difficulties. Several users have reported, and we have had confirmation in the log files, an annoying problem of "Internal Server Error".
NOTE: "Internal Server Error" is only temporary! If you should happen to receive this error will be sufficient a refresh the page!
We are working to resolve it as soon as possible! Please accept our apologies for the inconvenience.
But we want to remember you that, because of high number of connections and download publications from our database (kept up-to-date and made available online, see Related Researches below), it is growing more than expected by all of us, we have decided to advance the date by one year of the third revision of BeatingCancerCenter's site.
So, the new web site will replace this "old site" very soon!
Clarifications from M.D. Giuseppe Di Bella regarding Temodal (Temozolomide) and others chemotherapeutic drugs
To reassure some doubtful and perplexed patient, and to reply to some unfounded false and duplicitous criticism.
We report here some sentences taken from symposium proceedings by Prof. Luigi Di Bella to better explain some concept.
If the tumor is growing, and if the growth is regulated by growth factors that the DBM inhibits, is pointless to ask a protocol to confirm it. The DBM was born from scientific data and from truths acquired from the official science (i.e. numerous publication that support it!).
It is essential, instead of the impracticable and imaginary destruction of all the neoplastic elements, the realization of all the known possible conditions, that will hinder the development. It is essential to activate all the inhibitors of the known growth factors, with appropriate doses, and with the right timing.
The DBM protocol was born in this contest, the contest of life and not of poisoning and cellular death, and the method that panders or enhances vital reactions, without looking for, with statistical precision, the right doses to kill.
The tumor is the deflection from the day-to-day life, and for this reason is important to bring these deflection back to normal, though the magnification of all those instruments that the conventional Physiology treat as essential for a normal life. The DBM panders and magnify the vital reactions and the antitumor homeostasis to put this in a condition opposed to the onset and progression of the tumor.
M.D. Ph.D Giuseppe Di Bella - Somatostatin (analogues and/or derivatives) in oncology, the overlooked evidences - 19/Jul/2010 - Bologna (Italy)
The rationale, the aims, the components, the biochemical and physiological bases and the molecular biology mechanisms of action of the DBM are described. The tolerability, the clinical findings and the confirmation in the literature of the antitumoural efficacy of each individual component of the DBM, enhanced by the synergic factorial effect, are reported "The serious numerous irregularities that totally delegitimised the DBM experiments in 1998" (see below with complete transcription here) are also pointed out. The positive results achieved with the retrospective observational study on patients treated with the DBM are reported.
The current data in the literature on chemotherapy document a high degree of toxicity and a mortality percentage also reported by the Reuters Health Agency (Wesport, CT 2001-05-17): “Unexpected high mortality rates associated with chemotherapy regimen...”. This is confirmed by a study of the chemotherapy protocols for lymphoproliferative diseases (Atra et al. 1998) which reports a mortality rate of 11%, not caused by the tumour but solely by the chemotherapy.
The current survival of patients with tumours is mainly due to surgery, much less to radiotherapy, reaching 29% at 5 years (Richards et al. 2000). Of this 29%, only 2.1–2.5% is due to chemotherapy (Morgan et al. 2005). This fundamental publication is based on 14 years of observation, 225,000 patients and 22 types of tumour, aimed at ascertaining the true contribution of chemotherapy in achieving 5 years of survival (see "How effective is chemo therapy?").
Chemotherapy alone, without surgery, thus allows only 2.1–2.5% of patients to survive for 5 years, after which it has been ascertained that half of these patients who have survived for five years will die in the long-term as a result of their tumour (Lopez et al. 1998). Data from the recent conferences of the American Society of Clinical Oncology (ASCO) clearly show that in solid tumours monoclonal antibodies allow an average increase in survival of around two months, and only in rare cases, with or without associated chemotherapy, does this figure rise to or exceed four months.
Based on these data reported in the literature, we decided that it was appropriate to propose the new biological, physiological and rational therapy protocols of the DBM with greater efficacy and lower toxicity.
- 2015-03-31 20:33:54
Abstract BACKGROUND: Recently, melatonin has been associated with cancer both in vitro and in vivo. However, the value of melatonin in the treatment of cancer remains disputable…
- 2015-03-31 20:15:04
Abstract BACKGROUND: 1,25 dihydroxyvitamin D3 (1,25D) and retinoids may play an important role in preventing progression of prostate cancer. METHODS: We examined the ability…
- 2015-03-31 19:53:37
Abstract This review evaluates the published basic science and clinical reports related to the role of melatonin in reducing the side effects of aminoglycosides and the cancer c…
- 2015-03-31 20:33:54
- 2013-10-27 14:17:46
A paper finding that important experiments can't be reproduced suggests new drugs could be based on bad science The cancer researchers Glenn Begley - a consultant and former…
- 2013-10-07 09:36:04
Australian paper on chemotherapy An important paper has been published in the Journal of Clinical Oncology. This meta-analysis, entitled: "The Contribution of Cytotoxic Chem…
- 2013-07-19 13:00:19
Lancet Oncology: Long-term side-effects of new, targeted therapies in pediatric cancer patients. A University of Colorado Cancer Center review published in the journal Lanc…
- 2013-10-27 14:17:46